SCHEMBL23717652

SCHEMBL23717652

CCC(CC)N1CCc2cccc(C(F)(F)F)c21

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.42
CRHR1 P34998 5/20 0.38
SLC6A2 P23975 5/20 0.36
SLC6A4 P31645 5/20 0.36
AADAT Q8N5Z0 1/20 0.35
MC4R P32245 1/20 0.35
HTR1A P08908 1/20 0.35
NOTUM Q6P988 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
ALDH1A1 P00352 2/20 0.33
PKM P14618 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 1/20 0.33
POLB P06746 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
CCR3 P51677 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21725631 0.87 P2RX7 (0.35) P2RX7SLC6A2SLC6A4AADATMC4R
SCHEMBL21725628 0.83 P2RX7 (0.39) P2RX7SLC6A2SLC6A4AADATNOTUM
SCHEMBL12383658 0.80 SLC6A2 (0.40) SLC6A2SLC6A4MC4RHTR1A
SCHEMBL12383519 0.78 SLC6A2 (0.49) CRHR1SLC6A2SLC6A4HTR1A
SCHEMBL22193297 0.77 TRPV1 (0.41) P2RX7AADATHTR1ANOTUMTRPV1
SCHEMBL10311203 0.77 NOTUM (0.49) CRHR1SLC6A2SLC6A4HTR1ANOTUM
SCHEMBL21725629 0.74 AADAT (0.40) P2RX7AADATNOTUMTRPV1ALDH1A1
SCHEMBL12905310 0.72 AADAT (0.38) AADATMC4RNOTUMTRPV1ALDH1A1
SCHEMBL21859763 0.71 SLC6A2 (0.52) SLC6A2SLC6A4NOTUMALDH1A1KDM4E
SCHEMBL23717842 0.69 C5AR1 (0.33) P2RX7SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-01-31 US disclosed
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566015-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R P2RX7 628/4885CRHR1 15/4885SLC6A2 341/4885
US-20210238164-A1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC3R, MC1R, MC2R P2RX7 628/4885CRHR1 15/4885SLC6A2 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.